BioNTech to acquire CureVac for $1.25bn.

BioNTech, an immunotherapy company, agreed to acquire CureVac, a biotech company, for $1.25bn. “This transaction is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine. We intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years,” Ugur Sahin, BioNTech CEO and Co-Founder.